



Quality Excellence Overview

May 2020




Caring for you, sharing for life.



Turnaround time

LifeServe began providing Covid-19 Convalescent Plasma (CCP) in early April to our hospital customers. Our team worked diligently, along with many of our healthcare partners, to adopt and expand this program. Initially, our biggest hurdle was finding donors who qualified for the program. Once we started to get that information, the next hurdle was assuring that we had ABO compatible units for our patient orders. To further increase availability we began a program to titer type A plasma so those units could be more safely transfused to non A patients. While there is still a struggle nationally to meet requests, we are proud to currently be at a 100% fill rate. Below you can see data on turnaround time, fill rate, and overall collections since the start of our program.

Weekly




Monthly



Fill Rate



Collections to date



Information from our Technical Services Supervisor

COVID-19 Convalescent Plasma Program

With the impact COVID-19, LifeServe is challenged to continually adapt to meet the needs of our communities. LifeServe recently implemented our Convalescent Plasma program in response to the need for this product in the communities we service. COVID-19 Convalescent Plasma (CCP) administered to critically ill, SARS-CoV-19 positive patients with acute respiratory distress syndrome (ARDS) has shown improved clinical status in clinical trials. This treatment, known as convalescent plasma therapy, requires plasma from donors who have recently recovered from a COVID-19 infection. Individuals who have recovered from COVID-19 have antibodies in their plasma that through plasma donation may lead the recipient of the plasma to experience more rapid improvement. This is because the receipt of plasma from a donor who has recovered, may have the ability to fight the virus causing COVID-19.

LifeServe Blood Center is proud that we are helping in this effort at this critical time for our communities. We are actively screening and qualifying donors for this potentially lifesaving product and scheduling plasma collections from our first qualified donors as they reach their 28-day recovery.

For those interested in obtaining CCP for transfusion, we recommend enrolling your institution in Mayo Clinic's Expanded Access Protocol IND at <https://www.uscovidplasma.org>. In order to transfuse CCP, your Medical Center/Site must register for the Expanded Access Protocol. The physician must also register before enrolling a patient to receive the CCP.

Please visit our [website](#) resources for CCP information for Physicians and Blood Banks. The document titled "[CCP Information for Blood Banks](#)" includes up to date information on product codes, how to order CCP through BloodHub Service Orders, and billing reimbursement if enrolled in Mayo's Expanded Access Protocol.

Rachael Muhs MLS (ASCP)
Rachael.muhs@lifeservebloodcenter.org
515-309-4947